论文部分内容阅读
9月18日,经过二十余年苦心研制的抗癌中成药“金龙神清丸”被荣获黑龙江省科技进步二等奖。这不仅给研制者带来欣慰,也给广大癌症患者带来了福音。 癌症,已是严重危害人类身体健康的常见病,多发病。也是举世公认的难治病。全世界现有癌症患者约1400万人,每年新增癌症患者约600万人。据统计,我国每年约有160万人患癌症,正在超过心、脑血管疾病的死亡而跃居前位,因此,防治癌症的研究是医学工作者的头等大事和当务之急。
On September 18th, Jinlong Shenqing Pill, an anti-cancer proprietary Chinese medicine that has been painstakingly researched for more than two decades, was awarded the second prize for scientific and technological progress in Heilongjiang Province. This not only brings comfort to the developer, but also brings good news to cancer patients. Cancer is a common disease that seriously endangers the health of humans. It is also recognized as an intractable disease. There are about 14 million cancer patients in the world, and about 6 million new cancer patients are added each year. According to statistics, about 1.6 million people in China suffer from cancer each year and are leaping to the top of the deaths of cardiovascular and cerebrovascular diseases. Therefore, research on the prevention and treatment of cancer is a top priority and a top priority for medical workers.